Zurück zu Projekte

14446.1 PFLS-LS

Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment

Zusammenfassung

Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment

Weitere Texte

Abstract

Tumor cells escape poor oxygenation (hypoxia) by overexpression of Carbonic Anhydrases (CA), in particular CAIX and CAXII, which leads to a growth advantage with|increased metastasis formation and poor patient survival. siRNA targeting of both CA proteins reduces tumor growth in animal models but is hardly applicable in the clinic due to unfavourable in vivo PK/PD properties. As a novel therapeutic approach, we will generate fully human CAIX and CAXII inhibiting antibodies and combine them in a new bi-specific antibody format to target both CAs simultaneously.

Beteiligte

Marc van Dijk

Wirtschaftspartner

4-Antibody AG Pharmazentrum Marc van Dijk Hochbergerstrasse 60c 4057 Basel BS CH

Christoph Renner

Kontaktperson

christoph.renner@unibas.ch

Universitätsspital Basel Christoph Renner Spitalstrasse 21 / Petersgraben 4 4031 Basel BS CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2013-06-30
Enddatum
2015-12-31
Bewilligte Gesamtkosten
CHF 371058.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%